Abstract
Summary
North America fat reduction market is expected to reach USD 11,773.56 million by 2033 from USD 4,201.57 million in 2022, growing at a CAGR of 9.9% during the forecast period of 2023 to 2033.
Market Segmentation:
North America Fat Reduction Market, By Type (Surgical Fat Reduction, Non-Invasive Fat Reduction, and Minimally Invasive), Application (Abdominal Fat, Thighs Fat, Buttock Fat, Upper-Arm Fat, Facial Fat, and Knee Fat), Gender (Female, Male), Age Group (Adult, Geriatric, and Child), End-User (Hospitals, Multi-Specialty Clinics, Dermatology Centers, Medical Spas, and Beauty Centers), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors and Others), Country (U.S.,Canada, Mexico, Costa Rica, Dominican Republic, Panama, El Salvador, Guatemala, Honduras, Nicaragua) - Industry Trends and Forecast to 2033
Overview of North America Fat Reduction Market Dynamics
Driver
• Increasing demand for minimally invasive and non-invasive procedures
Restraint
• High cost of procedures
Opportunity
• Customized treatment plans and integration with other aesthetic procedures
Market Players:
Soe of the key market players operating in the North America fat reduction market are listed below:
• AbbVie Inc.
• Cynosure
• Candela Corporation
• Alma Lasers
• Solta Medical (Subsidiary of Bausch & Lomb Incorporated)
• Merz Pharma
• Cutera
• MicroAire Surgical Instruments, LLC.
• Others
Table of Contents
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW OF THE NORTH AMERICA FAT REDUCTION MARKET 38
1.4 CURRENCY AND PRICING 40
1.5 LIMITATIONS 40
1.6 MARKETS COVERED 41
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 DBMR TRIPOD DATA VALIDATION MODEL 47
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.6 MULTIVARIATE MODELLING 51
2.7 TYPE LIFELINE CURVE 51
2.8 DBMR MARKET POSITION GRID 52
2.9 VENDOR SHARE ANALYSIS 53
2.10 MARKET APPLICATION COVERAGE GRID 54
2.11 SECONDARY SOURCES 55
2.12 ASSUMPTIONS 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHT 58
4.1 PESTEL ANALYSIS 59
4.2 PORTER’S FIVE FORCES 60
4.3 BRAND ANALYSIS 61
4.3.1 KYBELLA 61
5 INDUSTRY INSIGHTS: 62
6 NORTH AMERICA FAT REDUCTION MARKET, REGULATIONS 64
6.1 U.S 64
6.1.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE: 64
6.1.2 POST-MARKETING SURVEILLANCE: 66
6.1.3 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES: 66
6.2 CANADA 67
6.2.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 67
6.2.2 LICENSING AND REGISTRATION 68
6.2.3 POST EXPIRY OF PATENT REGIME 68
6.2.4 POST-MARKETING SURVEILLANCE 68
6.3 MEXICO 69
6.3.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 69
6.3.2 REGULATORY APPROVAL AGENCIES 69
6.3.3 LICENSING AND REGISTRATION 70
6.3.4 POST-MARKETING SURVEILLANCE 70
7 MARKET OVERVIEW 71
7.1 DRIVERS 73
7.1.1 INCREASING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 73
7.1.2 GROWING AESTHETIC CONSCIOUSNESS AND BEAUTY STANDARDS 74
7.1.3 GROWING TECHNOLOGICAL ADVANCEMENTS 75
7.1.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 76
7.2 RESTRAINTS 77
7.2.1 HIGH COST OF PROCEDURES 77
7.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 78
7.2.3 PRODUCT RECALL 78
7.3 OPPORTUNITIES 79
7.3.1 CUSTOMIZED TREATMENT PLANS AND INTEGRATION WITH OTHER AESTHETIC PROCEDURES 79
7.3.2 BELIEF AND TREND OF FAT REDUCTION IN YOUNG ADULTS 80
7.3.3 FOCUS ON INCLUSIVITY AND DIVERSITY AND EXPANSION OF PRODUCT LINES 82
7.4 CHALLENGES 84
7.4.1 LONG-TERM EFFICACY AND SUSTAINABILITY 84
7.4.2 LONGER RECOVERY TIME OF THE PROCEDURE 84
8 NORTH AMERICA FAT REDUCTION MARKET, BY TYPE 86
8.1 OVERVIEW 87
8.2 SURGICAL FAT REDUCTION 90
8.2.1 LIPOSUCTION 91
- 8.2.1.1 BY TYPE 91
- 8.2.1.1.1 ULTRASOUND-ASSISTED LIPOSUCTION 91
- 8.2.1.1.2 LASER-ASSISTED LIPOSUCTION 91
- 8.2.1.1.3 TUMESCENT LIPOSUCTION 92
- 8.2.1.1.4 SUPER-WET TECHNIQUE 92
- 8.2.1.2 BY APPLICATION 92
- 8.2.1.2.1 ABDOMINAL FAT 93
- 8.2.1.2.2 THIGHS FAT 93
- 8.2.1.2.3 BUTTOCK FAT 93
- 8.2.1.2.4 UPPER-ARM FAT 93
- 8.2.1.2.5 FACIAL FAT-DEPOSITS 93
- 8.2.1.2.5.1 SUBMENTAL AREAS 94
- 8.2.1.2.5.2 MALAR 94
- 8.2.1.2.5.3 MANDIBULAR 94
- 8.2.1.2.6 KNEE FAT 94
- 8.2.1.1 BY TYPE 91
8.2.2 SURGICAL REJUVENATION 94
- 8.2.2.1 FACE LIFT 95
- 8.2.2.2 NECK LIFT 95
8.2.3 CHIN IMPLANT 95
- 8.2.3.1 SILICONE CHIN IMPLANTS 96
- 8.2.3.2 OTHERS 96
8.2.4 PORUS IMPLANTS 96
- 8.2.4.1 TEFLON 97
- 8.2.4.2 GORE-TEX 97
- 8.2.4.3 MEDPORE IMPLANTS 97
8.3 NON-INVASIVE FAT REDUCTION 97
8.3.1 CRYOLIPOLYSIS 99
- 8.3.1.1 COOL SCULPTING 99
- 8.3.1.2 COOL SCULPTING ELITE 99
- 8.3.1.3 COOL TONE 99
- 8.3.1.4 OTHERS 100
- 8.3.1.4.1 ABDOMINAL FAT 100
- 8.3.1.4.2 THIGHS FAT 100
- 8.3.1.4.3 BUTTOCK FAT 100
- 8.3.1.4.4 UPPER-ARM FAT 101
- 8.3.1.4.5 FACIAL FAT-DEPOSITS 101
- 8.3.1.4.6 KNEE FAT 101
8.3.2 ULTRASOUND 101
- 8.3.2.1 INTERNAL ULTRASONIC LIPOSUCTION 102
- 8.3.2.2 EXTERNAL ULTRASONIC LIPOSUCTION 102
- 8.3.2.2.1 ABDOMINAL FAT 102
- 8.3.2.2.2 THIGHS FAT 102
- 8.3.2.2.3 BUTTOCK FAT 103
- 8.3.2.2.4 UPPER-ARM FAT 103
- 8.3.2.2.5 FACIAL FAT-DEPOSITS 103
- 8.3.2.2.6 KNEE FAT 103
8.3.3 RADIOFREQUENCY 104
- 8.3.3.1 ABDOMINAL FAT 104
- 8.3.3.2 THIGHS FAT 104
- 8.3.3.3 BUTTOCK FAT 104
- 8.3.3.4 UPPER-ARM FAT 105
- 8.3.3.5 FACIAL FAT-DEPOSITS 105
- 8.3.3.6 KNEE FAT 105
8.3.4 LOW LEVEL LASER THERAPY 105
- 8.3.4.1 ABDOMINAL FAT 106
- 8.3.4.2 THIGHS FAT 106
- 8.3.4.3 BUTTOCK FAT 106
- 8.3.4.4 UPPER-ARM FAT 106
- 8.3.4.5 FACIAL FAT-DEPOSITS 106
- 8.3.4.6 KNEE FAT 106
8.3.5 OTHERS 106
8.4 MINIMALLY INVASIVE 106
8.4.1 INJECTION LIPOLYSIS 108
- 8.4.1.1 DEOXYCHOLIC ACID INJECTIONS 108
- 8.4.1.1.1 KYBELLA/BELKYRA 109
- 8.4.1.1.1.1 FACIAL FAT-DEPOSITS 110
- 8.4.1.1.1.2 UPPER-ARM FAT 110
- 8.4.1.1.1.3 ABDOMINAL FAT 110
- 8.4.1.1.1.4 THIGHS FAT 110
- 8.4.1.1.1.5 KNEE FAT 110
- 8.4.1.1.1.6 BUTTOCK FAT 110
- 8.4.1.1.1 KYBELLA/BELKYRA 109
- 8.4.1.2 PHOSPHATIDYLCHOLINE 111
- 8.4.1.2.1 FACIAL FAT-DEPOSITS 112
- 8.4.1.2.2 UPPER-ARM FAT 112
- 8.4.1.2.3 ABDOMINAL FAT 112
- 8.4.1.2.4 THIGHS FAT 112
- 8.4.1.2.5 KNEE FAT 112
- 8.4.1.2.6 BUTTOCK FAT 112
- 8.4.1.1 DEOXYCHOLIC ACID INJECTIONS 108
8.4.2 OTHERS 112
9 NORTH AMERICA FAT REDUCTION MARKET, BY APPLICATION 113
9.1 OVERVIEW 114
9.2 ABDOMINAL FAT 117
9.3 THIGHS FAT 117
9.4 BUTTOCK FAT 118
9.5 UPPER-ARM FAT 119
9.6 FACIAL FAT-DEPOSITS 119
9.6.1 SUBMENTAL AREAS 120
9.6.2 MANDIBULAR 120
9.6.3 MALAR 120
9.7 KNEE FAT 121
10 NORTH AMERICA FAT REDUCTION MARKET, BY GENDER 122
10.1 OVERVIEW 123
10.2 FEMALE 126
10.3 MALE 126
11 NORTH AMERICA FAT REDUCTION MARKET, BY AGE GROUP 127
11.1 OVERVIEW 128
11.2 ADULT 131
11.3 GERIATRIC 132
11.4 CHILD 132
12 NORTH AMERICA FAT REDUCTION MARKET, BY END USER 133
12.1 OVERVIEW 134
12.2 HOSPITALS 138
12.2.1 BY TYPE 138
- 12.2.1.1 PRIVATE 138
- 12.2.1.2 PUBLIC 139
12.2.2 BY CATEGORY 139
- 12.2.2.1 TIER 1 139
- 12.2.2.2 TIER 2 139
- 12.2.2.3 TIER 3 139
12.3 MULTISPECIALTY CLINICS 140
12.4 DERMATOLOGY CENTERS 140
12.5 MEDICAL SPAS AND BEAUTY CENTERS 141
12.6 OTHERS 141
13 NORTH AMERICA FAT REDUCTION MARKET, BY DISTRIBUTION CHANNEL 142
13.1 OVERVIEW 143
13.2 DIRECT TENDERS 146
13.3 RETAIL SALES 146
13.4 THIRD PARTY DISTRIBUTORS 147
13.5 OTHERS 147
14 NORTH AMERICA FAT REDUCTION MARKET, BY COUNTRY 148
14.1 NORTH AMERICA 148
14.1.1 U.S 152
14.1.2 CANADA 175
14.1.3 MEXICO 197
14.1.4 COSTA RICA 222
14.1.5 DOMINICAN REPUBLIC 248
14.1.6 PANAMA 273
14.1.7 EL SALVADOR 298
14.1.8 GUATEMALA 323
14.1.9 HONDURAS 347
14.1.10 NICARAGUA 372
15 COMPANY SHARE ANALYSIS: NORTH AMERICA 395
16 SWOT ANALYSIS 396
17 NORTH AMERICA FAT REDUCTION MARKET, COMPANY PROFILINGS 397
17.1 ABBVIE INC 397
17.1.1 COMPANY SNAPSHOT 397
17.1.2 REVENUE ANALYSIS 397
17.1.3 PRODUCT PORTFOLIO 398
17.1.4 RECENT DEVELOPMENTS 399
17.2 CYNOSURE 400
17.2.1 COMPANY SNAPSHOT 400
17.2.2 PRODUCT PORTFOLIO 400
17.2.3 RECENT DEVELOPMENTS 401
17.3 ALMA LASERS 402
17.3.1 COMPANY SNAPSHOT 402
17.3.2 PRODUCT PORTFOLIO 403
17.3.3 RECENT DEVELOPMENT 403
17.4 CANDELA CORPORATION 404
17.4.1 COMPANY SNAPSHOT 404
17.4.2 PRODUCT PORTFOLIO 404
17.4.3 RECENT DEVELOPMENT 404
17.5 MERZ NORTH AMERICA, INC 405
17.5.1 COMPANY SNAPSHOT 405
17.5.2 PRODUCT PORTFOLIO 405
17.5.3 RECENT DEVELOPMENTS 406
17.6 BLACK & BLACK SURGICAL 407
17.6.1 COMPANY SNAPSHOT 407
17.6.2 PRODUCT PORTFOLIO 407
17.6.3 RECENT DEVELOPMENT 407
17.7 BTL GROUP OF COMPANIES 408
17.7.1 COMPANY SNAPSHOT 408
17.7.2 PRODUCT PORTFOLIO 408
17.7.3 RECENT DEVELOPMENTS 408
17.8 BAUSCH HEALTH COMPANIES INC 409
17.8.1 COMPANY SNAPSHOT 409
17.8.2 REVENUE ANALYSIS 409
17.8.3 PRODUCT PORTFOLIO 410
17.8.4 RECENT DEVELOPMENT 410
17.9 CUTERA 411
17.9.1 COMPANY SNAPSHOT 411
17.9.2 REVENUE ANALYSIS 411
17.9.3 PRODUCT PORTFOLIO 412
17.9.4 RECENT DEVELOPMENT 412
17.10 ERCHONIA CORPORATION 413
17.10.1 COMPANY SNAPSHOT 413
17.10.2 PRODUCT PORTFOLIO 413
17.10.3 RECENT DEVELOPMENT 413
17.11 FOTONA 414
17.11.1 COMPANY SNAPSHOT 414
17.11.2 PRODUCT PORTFOLIO 414
17.11.3 RECENT DEVELOPMENT 414
17.12 GENESIS BIOSYSTEMS, INC 415
17.12.1 COMPANY SNAPSHOT 415
17.12.2 PRODUCT PORTFOLIO 415
17.12.3 RECENT DEVELOPMENT 415
17.13 HIRONIC CO., LTD 416
17.13.1 COMPANY SNAPSHOT 416
17.13.2 REVENUE ANALYSIS 416
17.13.3 PRODUCT PORTFOLIO 417
17.13.4 RECENT DEVELOPMENT 417
17.14 IMPLANTECH 418
17.14.1 COMPANY SNAPSHOT 418
17.14.2 PRODUCT PORTFOLIO 418
17.14.3 RECENT DEVELOPMENTS 419
17.15 LEADERMA INC 420
17.15.1 COMPANY SNAPSHOT 420
17.15.2 PRODUCT PORTFOLIO 420
17.15.3 RECENT DEVELOPMENT 420
17.16 LYNTON LASERS LTD 421
17.16.1 COMPANY SNAPSHOT 421
17.16.2 PRODUCT PORTFOLIO 421
17.16.3 RECENT DEVELOPMENT 421
17.17 MENTOR WORLDWIDE LLC (A PART OF JOHNSON & JOHNSON SERVICES, INC.) 422
17.17.1 COMPANY SNAPSHOT 422
17.17.2 REVENUE ANALYSIS 422
17.17.3 PRODUCT PORTFOLIO 423
17.17.4 RECENT DEVELOPMENT 423
17.18 MICROAIRE SURGICAL INSTRUMENTS, LLC 424
17.18.1 COMPANY SNAPSHOT 424
17.18.2 PRODUCT PORTFOLIO 424
17.18.3 RECENT DEVELOPMENT 424
17.19 MOLLER MEDICAL 425
17.19.1 COMPANY SNAPSHOT 425
17.19.2 PRODUCT PORTFOLIO 425
17.19.3 RECENT DEVELOPMENT 425
17.20 POLLOGEN (A SUBSIDIARY OF LUMENIS BE LTD.) 426
17.20.1 COMPANY SNAPSHOT 426
17.20.2 PRODUCT PORTFOLIO 426
17.20.3 RECENT DEVELOPMENT 426
17.21 SILIMED 427
17.21.1 COMPANY SNAPSHOT 427
17.21.2 PRODUCT PORTFOLIO 427
17.21.3 RECENT DEVELOPMENTS 427
17.22 SURGIFORM INNOVATIVE SURGICAL PRODUCTS 428
17.22.1 COMPANY SNAPSHOT 428
17.22.2 PRODUCT PORTFOLIO 428
17.22.3 RECENT DEVELOPMENT 428
17.23 VENUS CONCEPT 429
17.23.1 COMPANY SNAPSHOT 429
17.23.2 REVENUE ANALYSIS 429
17.23.3 PRODUCT PORTFOLIO 430
17.23.4 RECENT DEVELOPMENT 430
18 QUESTIONNAIRE 431
19 RELATED REPORTS 435